During the past decade, GI Research Institute conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 22 clinical trials were completed, i.e. on average, 51.2% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 14 clinical trials were completed. i.e. 77.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "GI Research Institute" #1 sponsor was "Gilead Sciences" with 14 trials, followed by "Celgene" with 10 trials sponsored, "Janssen Research & Development, LLC" with 6 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored and "Assembly Biosciences" with 5 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "GI Research Institute" #1 collaborator was "Algorithme Pharma Inc" with 1 trials as a collaborator, "Ironwood Pharmaceuticals, Inc." with 1 trials as a collaborator, "JSS Medical Research Inc." with 1 trials as a collaborator, "PRA Health Sciences" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "GI Research Institute" are "Ulcerative Colitis" (10 trials), "Crohn's Disease" (8 trials), "Crohn Disease" (6 trials), "Hepatitis B, Chronic" (5 trials) and "Chronic Hepatitis B" (4 trials). Many other conditions were trialed in "GI Research Institute" in a lesser frequency.

Most popular intervention types in "GI Research Institute" are "Drug" (53 trials), "Other" (9 trials), "Biological" (7 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "GED-0301" (5 trials), "RBV" (5 trials), "Mirikizumab" (4 trials) and "TAF" (4 trials). Other intervention names were less common.

The vast majority of trials in "GI Research Institute" are 63 trials for "All" genders.

Currently, there are NaN active trials in "GI Research Institute". undefined are not yet recruiting, 12 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 35 completed trials in GI Research Institute, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in GI Research Institute, 3 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".